The TB Vaccine Advocacy Roadmap (TB Vax ARM) will hold its first virtual meeting of the year on 14 February 2024 with updates on key news and developments from the field from Treatment Action Group, FIND, and IAVI:

With a $300,000 grant, the Welch Foundation is supporting University of Texas at Arlington (UTA) research into why some types of Mycobacterium tuberculosis (Mtb), the bacteria that causes the lung disease tuberculosis (TB), do not respond to treatments.

RESIST-TB released its February 2024 newsletter with the latest updates and research publications on drug-resistant TB.

LifeArc and the Bill & Melinda Gates Foundation are jointly investing £6 million ($7.2m) in the Grand Challenges African Drug Discovery Accelerator (GC ADDA) programme, a collaboration that will support 5 African drug discovery projects over 3 to 5 years.

WHO releases a policy brief summarizing key WHO guidance on identifying the primary opportunistic infections among people with advanced HIV disease, including TB.

At the 2023 Union Conference, TAG's Lindsay McKenna sat down with Denis Godlevsky of ITPC EECA for a wide-ranging discussion on TB research, activism, and TAG's historic + present role shaping both.

Healthcare providers and policymakers in LMICs are invited to take part in an online survey assessing their perspectives on long-acting TB preventive treatment.

Médecins Sans Frontières releases a factsheet outlining the current scenario of diagnosing TB in children and making recommendations to test developers for needed improvements.

WHO publishes a document summarizing evidence gaps articulated in various WHO TB policy guidance to help steer innovation towards sustainable public health interventions required to end TB.

Immune checkpoint inhibitor (ICI) treatment may increase the risk of tuberculosis reactivation or latent tuberculosis infection in patients with cancer, according to research published in The Oncologist.